Johnson & Johnson Applies For Emergency Use Authorization for Anti-COVID-19 Vaccine

A dosage of the Pfizer COVID-19 vaccine in New York, 2020. Johnson & & Johnson is the third vaccine candidate to make an application for emergency situation use authorization from the FDA. The vaccine needs a single dosage and does not need ultra-cold temperature levels for storage.

Mary Altaffer/AP

toggle caption

hide caption

Mary Altaffer/AP

A dosage of the Pfizer COVID-19 vaccine in New York, 2020. Johnson & & Johnson is the third vaccine prospect to make an application for emergency situation usage authorization from the FDA. The vaccine needs a single dosage and does not require ultra-cold temperatures for storage.

Mary Altaffer/AP

In a statement launched Thursday, the company said if emergency use is given, it aims to supply 100 million doses in the very first half of 2021. Unlike Pfizer and Moderna, Johnson & & Johnsons Janssen vaccine can be kept for a minimum of three months at 36-46 degrees Fahrenheit, compatible with standard vaccine circulation channels, the business stated.

The FDA is expected to hold a public meeting of outdoors advisers within a couple of weeks. If the advisers favor the vaccine, a decision authorize its use could come soon later on.

” The possible to considerably decrease the concern of severe illness, by supplying a well-tolerated and efficient vaccine with simply one immunization, is a crucial part of the global public health response,” stated Paul Stoffels, Johnson & & Johnson vice chairman of the executive committee and chief scientific officer. “Eighty-five percent effectiveness in preventing extreme COVID-19 disease and prevention of COVID-19-related medical interventions will possibly secure numerous countless people from serious and deadly results of COVID-19.”

It has revealed to be 66% effective total in preventing moderate to extreme COVID-19 4 weeks after the shot is administered. Johnson & & Johnson stated the vaccine was 72% reliable in the United States, compared to 66% in Latin America and 57% in South Africa.

A dosage of the Pfizer COVID-19 vaccine in New York, 2020. The vaccine requires a single dose and doesnt require ultra-cold temperature levels for storage.

A dose of the Pfizer COVID-19 vaccine in New York, 2020. The vaccine requires a single dose and doesnt need ultra-cold temperatures for storage.

However, the vaccine is 85% efficient in avoiding serious kinds of COVID-19. And the effectiveness of the treatment increased over time, the company stated, without any cases in immunized individuals after 49 days.

A 3rd coronavirus vaccine prospect has actually requested emergency situation usage permission from the Food and Drug Administration. Johnson & & Johnson sent its application Thursday for the businesss single-dose inoculation.